The structures in question are neutrophil extracellular traps, or NETs, gossamer lattices of DNA studded with toxic proteins that neutrophils release to ensnare bacteria and fungi. Discovered only in 2004, NETs have since been implicated in a growing list of diseases far removed from infection, including autoimmune disorders, cancer metastasis, and cardiovascular disease. In the context of stroke, they occupy a particularly dangerous intersection between two pathological processes: inflammation and coagulation. The DNA scaffolds of NETs provide a surface onto which platelets aggregate and fibrin deposits, while the embedded enzymes, such as neutrophil elastase and myeloperoxidase, can damage the delicate endothelial lining of blood vessels. This coupling of clot formation and tissue inflammation has been termed thromboinflammation, and it is precisely the mechanism the researchers suspected might link high blood sugar to bleeding in the brain.

To test that hypothesis, the team led by Ziyuan Zhao, Yiming Ma, and senior authors Lianhua Fang and Linglei Kong of the Institute of Materia Medica at the Chinese Academy of Medical Sciences and Peking Union Medical College began with a computational approach. They mined publicly available gene expression datasets from the Gene Expression Omnibus, searching for molecular pathways that distinguish hyperglycemia-induced hemorrhagic transformation from ordinary ischemic injury. The analysis pointed repeatedly toward neutrophil activation and NET formation, suggesting that the regulatory circuits governing these immune webs were among the most prominent signatures of the complication.

Computational predictions, however, are only as good as their validation in biological systems. The researchers next turned to human samples, measuring NET levels in blood drawn from stroke patients and comparing them against circulating glucose concentrations. The correlation was clear and positive: the higher a patient’s blood glucose, the greater the burden of NETs in their bloodstream. The team also collected neutrophils from rats and exposed them to hyperglycemic conditions in the laboratory, observing that elevated glucose drove the white blood cells to expel more of their DNA-based traps. Together, these findings established the first pillar of the study’s argument: hyperglycemia and NET formation are not merely coincidental features of severe stroke but appear to be mechanistically intertwined.

The second pillar came from animal experiments. The researchers induced ischemic stroke in rats by occluding the middle cerebral artery, the standard model of human ischemic stroke, while simultaneously rendering the animals hyperglycemic. They then tracked both NET levels and cerebral hemorrhage over time. The results were striking in their synchrony: NET burden and brain hemoglobin content, a direct measure of bleeding, both peaked one day after the stroke, and the severity of hemorrhagic transformation rose in a linear relationship with the amount of NETs present. In other words, the more DNA webs circulating in the vasculature and infiltrating the brain, the worse the bleeding, a dose-response pattern that strengthens the case for a causal connection.

Correlation alone, however, rarely satisfies the standards of translational research, so the team moved to intervention. They treated the hyperglycemic stroke rats with two complementary agents targeting NETs by different mechanisms. The first, Cl-amidine, inhibits peptidyl arginine deiminase 4, or PAD4, the enzyme responsible for the citrullination of histones that loosens chromatin and allows neutrophils to release their traps. At a dose of 20 milligrams per kilogram given intraperitoneally, Cl-amidine prevents NETs from forming in the first place. The second, DNase I, is an enzyme that chops up the DNA backbone of already-released NETs, effectively dissolving existing webs; it was administered intravenously at 10 milligrams per kilogram. Both strategies produced the same outcome: significantly reduced hemorrhagic transformation in the hyperglycemic rats. That two mechanistically distinct interventions converged on the same protective effect is among the strongest forms of evidence available in preclinical pharmacology, and it argues that NETs are not a bystander in this process but an active driver.

Having established that NETs matter, the researchers probed how they inflict their damage. Using RNA sequencing of brain tissue, immunofluorescence microscopy, and enzyme-linked immunosorbent assays, they mapped the molecular fallout of NET accumulation. The picture that emerged was one of runaway thromboinflammation. Rats with abundant NETs showed elevated levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-8, signaling molecules that recruit further immune cells and amplify tissue damage. At the same time, the animals displayed increased concentrations of thrombosis-related factors, among them von Willebrand factor, a glycoprotein that promotes platelet adhesion; thrombin-antithrombin complexes, a marker of active clot formation; and fibrinogen, the soluble precursor of the fibrin mesh that solidifies clots. The coexistence of heightened inflammation and heightened coagulation in the same animals captures the essence of thromboinflammation: a self-reinforcing loop in which clotting provokes immune activation and immune activation provokes further clotting.

The consequences of this loop for the blood-brain barrier are particularly consequential. The barrier, a tightly sealed layer of endothelial cells joined by protein complexes such as zonula occludens-1, normally shields the brain from blood-borne molecules and cells. NETs and their associated inflammatory mediators are known to degrade the proteins that hold these junctions together, and matrix metalloproteinase-9, an enzyme released by neutrophils, can chew through the basement membrane supporting the vessel wall. When the barrier fails, red blood cells and plasma proteins flood into brain parenchyma, converting an ischemic lesion into a hemorrhagic one. The study’s finding that NET inhibition preserved barrier integrity and reduced bleeding is consistent with this mechanism, although the authors note that the full cascade of downstream events remains to be worked out in detail.

The clinical implications of the work are twofold. First, NETs may serve as a biomarker. Because NET levels correlated with blood glucose in patients and with hemorrhage severity in rats, a simple blood test measuring NET components, such as circulating cell-free DNA, myeloperoxidase-DNA complexes, or nucleosomes, could potentially identify which hyperglycemic stroke patients are at highest risk of hemorrhagic transformation before it occurs. This would be invaluable in decisions about reperfusion therapy, where physicians must weigh the benefit of restoring blood flow against the danger of provoking bleeding into tissue that has been rendered fragile by inflammation. Second, NETs represent a therapeutic target. Drugs that inhibit PAD4 or degrade extracellular DNA already exist in some form; DNase I, for instance, is an approved therapy for cystic fibrosis, where it liquefies DNA-rich mucus in the lungs. Repurposing such agents for stroke would face substantial hurdles, including the challenge of delivering them across the blood-brain barrier and the risk of impairing neutrophil-mediated host defense, but the present study provides the preclinical proof of concept that such an approach could work.

Cautious optimism is warranted. The findings come from rat models and a modest human correlative dataset, and rodent stroke research has a long history of therapies that succeeded in animals but failed in human trials. Hyperglycemia in the laboratory, typically induced acutely, may not fully recapitulate the chronic vascular damage seen in diabetic patients. Nevertheless, the study is the first to directly implicate NETs in hyperglycemia-induced hemorrhagic transformation, and it does so with a methodological rigor that spans computational prediction, human correlation, dose-response modeling, and dual-pharmacological intervention. As the prevalence of diabetes continues to rise worldwide, and with it the number of strokes occurring in hyperglycemic brains, the need for such mechanistic insights has never been greater. If future studies confirm that neutrophil webs are the thread connecting sugar and bleeding in the injured brain, unraveling them may become one of the most consequential interventions in acute stroke medicine.

Subject of Research: The role of neutrophil extracellular traps in hyperglycemia-induced hemorrhagic transformation after ischemic stroke

Article Title: Inhibition of NETs-mediated thromboinflammation alleviates hemorrhagic transformation after hyperglycemic stroke

Article References: Zhao, Z., Ma, Y., Sun, W., Liu, C., Wang, L., Jiang, Y., Du, G., Fang, L., & Kong, L. (2026). Inhibition of NETs-mediated thromboinflammation alleviates hemorrhagic transformation after hyperglycemic stroke. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08901-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08901-9

Keywords: stroke, hemorrhagic transformation, hyperglycemia, neutrophil extracellular traps, thromboinflammation, PAD4, DNase I, blood-brain barrier, inflammation, coagulation, biomarker, Journal of Translational Medicine

The mechanistic heart of the review is the positive feedback loop it describes between cancer cells, tumor-associated neutrophils and NETs. Tumor cells orchestrate the reprogramming of neutrophils through paracrine signaling: they secrete chemokines such as CXCL1 and CXCL2, which recruit neutrophils via the CXCR1 and CXCR2 receptors, and cytokines including IL-1β, IL-8, granulocyte colony-stimulating factor and tumor-derived exosomes carrying mutant KRAS. Once in the tumor microenvironment, these neutrophils can be pushed toward NET formation by hypoxia, acidity, collagen signaling through DDR1, and stromal inputs from cancer-associated fibroblasts. The NETs themselves then feed back on the tumor, activating pro-growth pathways such as ERK and NF-κB, promoting epithelial-mesenchymal transition and reinforcing the very signals that recruit more neutrophils. This self-amplifying circuit explains why circulating and tumor-infiltrating NETs correlate so consistently with advanced disease in breast, pancreatic, gastric, colorectal and hepatocellular cancers, among others studied to date.

At the molecular level, NET formation, or NETosis, is a carefully choreographed demolition of the neutrophil’s own architecture. In the classical suicidal pathway, signaling through reactive oxygen species generated by the NADPH oxidase complex activates protein arginine deiminase 4, or PAD4, an enzyme that hypercitrullinates histone H3. Citrullination loosens the electrostatic grip of histones on DNA, driving chromatin decondensation, nuclear envelope breakdown and ultimately the explosive extrusion of decondensed DNA decorated with granule proteins. Neutrophil elastase and myeloperoxidase translocate to the nucleus to assist this dismantling, while cathepsin G and proteinase 3 join the final trap. Alternative routes exist as well: viable neutrophils can expel mitochondrial DNA to form traps without dying, and rapid, nuclear-based release has been documented within minutes of certain bacterial encounters. Which pathway dominates appears to depend on the stimulus, a specificity confirmed by comparative proteomic analyses showing that NETs induced by different triggers carry distinct protein cargoes.

As weapons of metastasis, NETs act on several fronts simultaneously. Their DNA scaffolds physically enmesh circulating tumor cells in the bloodstream, increasing adhesion to the vascular endothelium and creating a protective nidus in which disseminated cells can extravasate and colonize distant organs. Proteases embedded in the traps, notably matrix metalloproteinase-9 and neutrophil elastase, remodel the extracellular matrix and, in pancreatic cancer, activate quiescent stellate cells and cancer-associated fibroblasts that prepare fertile ground for micrometastases. Landmark work in mice showed that NETs produced during inflammation can rouse dormant cancer cells, explaining recurrences years after primary tumor removal. The traps also subvert immunity directly: NET-associated DNA can bind TMCO6 on T cells to impair CD8-positive cytotoxic function, upregulate the immunosuppressive enzyme CD73, decorate themselves with PD-L1, promote T cell exhaustion and foster T regulatory cell infiltration. In this sense, NETs function as both physical scaffolds for spread and chemical camouflage against the immune system, a dual role that the review identifies as central to immune evasion and distant metastasis.

The consequences extend to treatment resistance, one of oncology’s most stubborn bottlenecks. NETs generated during chemotherapy confer resistance by activating latent TGF-β, while the dense DNA matrix limits the diffusion of drugs such as doxorubicin, blunting its ability to trigger apoptosis in ovarian cancer cells. In bladder cancer, NETs contribute to radiation resistance, and low-dose ionizing radiation itself can provoke NET extrusion, an unsettling feedback. Immune checkpoint blockade suffers too: NET formation driven by IL-17 signaling mediates resistance in pancreatic cancer, cirrhotic extracellular matrix initiates immunosuppressive NETs that attenuate anti-PD-1 responses in hepatocellular carcinoma, and IGF2BP3-induced NETosis undermines oncolytic virotherapy in malignant glioma. Conversely, the review emphasizes that targeted disruption of the NET axis reverses these resistances and sensitizes tumors to radiotherapy, chemotherapy and checkpoint inhibitors, positioning NETs as genuinely novel therapeutic targets rather than mere biomarkers of misfortune.

A notable theme of the review is the breadth of candidate drugs capable of disarming the NET machinery, many of them repurposed from other fields. Anthracyclines suppress both NADPH oxidase-dependent and -independent NETosis; the antiparasitic ivermectin abrogates NETs and prevents melanoma metastasis in preclinical models; chloroquine and hydroxychloroquine reduce trap formation partly by inhibiting PAD4; and the glucagon-like peptide-1 receptor agonists liraglutide and exenatide enhance checkpoint blockade efficacy by attenuating NETs in lung and liver cancers. Metformin mitigates obesity-driven NET-driven tumor aggressiveness in mice, the nuclear export inhibitor selinexor blocks human NET formation in vitro, and histidine-rich glycoprotein suppresses hepatic metastatic seeding. Even traditional Chinese medicine formulations, from Huang Qin Decoction to Pi Ji Pills, and phytochemicals such as kaempferol, resveratrol, epigallocatechin-3-gallate and emodin, have been shown to interfere with the ROS-PAD4, STAT3-CXCL8 and PI3K-AKT pathways that drive trap formation. Biomaterials approaches, including NET-degrading enzyme hydrogels applied after surgery, and localized photoregulated enzyme delivery, offer physically targeted ways to dismantle traps at metastatic sites.

Translating these discoveries into the clinic depends on measuring NETs reliably, and the review devotes substantial attention to detection technology. The most widely used circulating markers are cell-free DNA, nucleosomes, myeloperoxidase-DNA and neutrophil elastase-DNA complexes, and citrullinated histone H3, the latter quantified by increasingly refined enzyme-linked immunosorbent assays validated in human plasma. Flow cytometric assays allow direct enumeration of NET-bearing structures in blood, atomic force microscopy has resolved the physical architecture of individual traps, and microfluidic chips can capture chromatin fibers from a single drop of blood, while computational image-analysis algorithms now standardize histological quantification. Clinically, peripheral blood NET biomarkers have been associated with diagnosis and progression of malignant tumors, trap-associated CEACAM1 has been proposed as a therapeutic target in metastatic colon cancer, and PD-L1-positive neutrophils releasing NETs in malignant ascites show promise as a hepatocellular carcinoma biomarker. Gene-expression signatures built around NET-related genes and long non-coding RNAs predict prognosis and immunotherapy response across gastric, breast, colon, lung, head-and-neck and soft-tissue cancers, although the review cautions that inconsistent findings and tumor heterogeneity still constrain their deployment.

The prognostic potential is especially striking. Tumor-infiltrating NETs predict post-surgical survival in pancreatic ductal adenocarcinoma, blood NETosis correlates with progression in head and neck cancer, pan-cancer signatures built from NET-associated genes stratify patient outcomes, and a NET-score has emerged as a prognostic marker in colorectal cancer. NETs also influence cancer-associated thrombosis, a major cause of morbidity: tumor-derived exosomes induce NETs that establish hypercoagulability, and IL-1β blockade attenuates thrombosis in NET-dependent breast cancer models. Yet the review is candid about limitations. Detection technologies remain imperfect and poorly standardized, prognostic modeling must contend with heterogeneous patient populations, and some research findings conflict, reflecting context-dependent roles of neutrophil subsets that range from antitumor to pro-tumor. Aging itself alters NET biology, complicating extrapolation from young animal models to elderly patients. Future work, the authors argue, should prioritize optimizing detection methods, conducting rigorous clinical validation and identifying tumor-type-specific therapeutic targets.

The broader message is that the immune defense once celebrated for strangling microbes has become a central hub in cancer biology, one that links inflammation, dormancy, metastasis, thrombosis and treatment failure within a single mechanistic framework. By mapping the regulatory factors, from PAD4 and neutrophil elastase to CXCL chemokines and TGF-β, and by cataloguing both the pharmacological and biomaterial tools that can interrupt them, the review provides a theoretical basis for bringing NETs into precision oncology. If the technical and validation challenges can be overcome, clinicians may one day read a patient’s NET profile the way they now read hormone receptor status, and use NET-disrupting agents to prevent metastasis and sensitize tumors to the therapies already at hand. For now, the convergence of mechanistic insight, assay development and drug repurposing suggests that a web once woven for defense is becoming an actionable thread in the fight against cancer.

Subject of Research: Neutrophil extracellular traps in tumor progression, detection and diagnosis

Article Title: Neutrophil extracellular traps in tumor progression: from mechanistic insights and regulatory factors to clinical detection and diagnosis

Article References: Zhang, Y., Zeng, Z., Xiong, W., Luo, J., & Fan, C. (2026). Neutrophil extracellular traps in tumor progression: from mechanistic insights and regulatory factors to clinical detection and diagnosis. Journal of Molecular Medicine, 104(1), Article 104. https://doi.org/10.1007/s00109-026-02709-2

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02709-2

Keywords: neutrophil extracellular traps, tumor-associated neutrophils, metastasis, immune evasion, therapy resistance, PAD4, cancer biomarkers, tumor microenvironment, diagnosis, checkpoint blockade, NETosis, precision oncology